This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam's (ALNY) Impressive Pipeline Drives Share Price
by Zacks Equity Research
Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.
Alnylam Files Application for Hypertension Candidate in UK
by Zacks Equity Research
Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.
Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam Stock Down Despite Positive Phase III Givosiran Data
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.
Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.
Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 7.61% and 67.92%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
5 Best Biotech Bets Likely to Outperform Estimates in Q4
by Zacks Equity Research
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs
by Zacks Equity Research
A low key week for the biotech sector with regular drug approvals and pipeline updates.
Alnylam & Medison Partner to Market RNAi Products in Israel
by Zacks Equity Research
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
Pfizer Gets FDA's Priority Review for Rare Disease Candidate
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
by Zacks Equity Research
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
by Zacks Equity Research
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
Alnylam (ALNY) Surges: Stock Moves 8.7% Higher
by Zacks Equity Research
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
Why Is Alnylam (ALNY) Up 9.2% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate
by Zacks Equity Research
Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chronic HBV infection.
Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus
by Zacks Equity Research
The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.
Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs wider-than-expected loss year over year in the third quarter of 2018 and reiterates guidance for the year.
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 9.83% and -89.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
Tenet Healthcare (THC) Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) third quarter earnings is likely to gain from solid performance by the Conifer Segment
Is a Disappointment in Store for bluebird (BLUE) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when bluebird (BLUE) reports third-quarter results.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.